Ergometrine is a potent ergot alkaloid derived from the fungus *Claviceps purpurea*, which grows on rye and other grains. In Nigerian maternity units, it stands as a cornerstone drug for saving mothers from postpartum hemorrhage, the leading cause of maternal mortality. Unlike oxytocin, which acts gently and requires a continuous IV infusion to maintain tone, ergometrine brings a rapid, sustained contraction of the myometrium. Midwives have relied on this medication for decades because it works reliably even in low-resource settings where cold-chain storage might occasionally fluctuate, though maintaining proper temperature remains vital for drug potency.
The drug exerts its powerful uterotonic effect by directly stimulating alpha-adrenergic and serotonergic receptors located within the smooth muscle of the uterine wall. When ergometrine binds to these receptors, it triggers a marked increase in intracellular calcium ions, causing the myometrium to undergo tetanic contractions. This means the uterine muscle fibers shorten and stay contracted, compressing the local blood vessels that previously fed the placental site. Beyond the uterus, ergometrine also causes widespread vasoconstriction throughout the mother's systemic circulation by acting on blood vessel walls.
Ergometrine is strictly indicated for situations involving uterine atony and postpartum hemorrhage. Midwives administer it during the third stage of labor or immediately following the delivery of the baby and placenta to prevent excessive blood loss. Sometimes, it is combined with oxytocin in a fixed-dose tablet or injection known as syntometrine, which captures the rapid onset of oxytocin and the sustained action of ergometrine. It is never used to induce labor or to speed up delivery while the baby is still inside the womb.
Midwives administer ergometrine through intramuscular (IM) or intravenous (IV) routes.
Because ergometrine causes profound vasoconstriction and raises systemic vascular resistance, it is strictly forbidden in several clinical scenarios. Midwives must review the antenatal card and assess the mother's medical history before reaching for the ampoule.
Most mothers tolerate a single dose of ergometrine well, but side effects can occur due to its action on smooth muscle throughout the body. Nausea and vomiting are very common immediately following an injection, sometimes managed with antiemetics if severe. More concerning is transient hypertension, which can cause severe headaches, dizziness, or chest discomfort. In rare cases of sensitivity or overdose, prolonged arterial spasm can lead to peripheral ischemia, where fingers and toes turn cold and pale.
Safe use of ergometrine requires careful midwifery oversight from storage to administration. Ampoules must be protected from light and kept in cool conditions to prevent chemical degradation that renders the drug useless. After giving the injection, the midwife must regularly palpate the abdomen to ensure the uterus remains well-contracted and firm. Blood pressure checks are essential to catch unexpected hypertension early. Finally, midwives must document the exact time, route, and dosage given in the patient's labor record.